Reach Us +1-217-403-9671
Management of the Spectrum of Essential Hypertension: A 2013 Perspective | OMICS International | Abstract
ISSN: 2329-6607

Cardiovascular Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Management of the Spectrum of Essential Hypertension: A 2013 Perspective

Cristian Riella and Theodore I Steinman*

Department of Medicine, Nephrology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, USA

Corresponding Author:
Theodore I Steinman
Department of Medicine, Nephrology Division
Beth Israel Deaconess Medical Center and Harvard Medical School
330 Brookline Ave., Boston, MA 02215, USA
Tel: 617-667-5278
Fax: 617-975-5595
E-mail: [email protected]

Received June 19, 2013; Accepted August 29, 2013; Published September 05, 2013

Citation: Riella C, Steinman TI (2013) Management of the Spectrum of Essential Hypertension: A 2013 Perspective. Cardiol Pharmacol 2:112. doi: 10.4172/2329-6607.1000112

Copyright: © 2013 Riella C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Management of hypertension: The association of hypertension with cardiovascular and renal disease is continuous and independent of other risk factors. Despite the increase in awareness and treatment of hypertension in the past decade, less than 50% of adults in the U.S have adequate blood pressure control. Every 10% increase in the treatment of patients with hypertension could prevent an additional 14,000 deaths. This article reviews the latest evidence guiding current hypertension management.
The main classes of drugs used to treat hypertension are diuretics (thiazides, loop and aldosterone antagonists), angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers. Alpha-adrenergic blockers and direct renin inhibitors are used infrequently and are mostly used as the 4th or 5th added agent.
No consensus has been established on initial drug choice. In patients with compelling indications, such as ischemic heart disease, diabetes, chronic kidney disease and stroke, some classes have shown greater benefits. Widely accepted is that blood pressure reduction is the most important determinant in lowering cardiovascular risk when there is no indication for a particular class of drugs. Hypertensive patients with central and peripheral vascular disease, chronic kidney disease and diabetes should have a lower target blood pressure.
In patients with mild primary hypertension undergoing monotherapy, with inadequate blood pressure control, sequential monotherapy may be attempted prior to adding another drug. Combination therapy should be considered from the onset in individuals with blood pressures that exceed 20/10 mmHg above the set target range.
The combination of angiotensin converting enzyme inhibitor plus a calcium channel blocker has been proven to be superior to other combinations. Considering the impact that adequate treatment can make in preventing deaths, the challenge is to improve access to care of patients with hypertension.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version